UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 113

Sortiert nach

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial

Diabetes, obesity & metabolism, 2011-10, Vol.13 (10), p.928-938

2011

Volltextzugriff (PDF)

Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre

Journal of Crohn's and colitis, 2020-07, Vol.14 (7), p.915-919

2020

Volltextzugriff (PDF)

A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts

Scandinavian journal of gastroenterology, 2022-07, Vol.57 (7), p.814-824

2022

Volltextzugriff (PDF)

Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre

Digestive diseases (Basel), 2017-01, Vol.35 (1-2), p.91-100

2017

Volltextzugriff (PDF)

Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial

Diabetes, obesity & metabolism, 2015-01, Vol.17 (1), p.42-51

2015

Volltextzugriff (PDF)

Advances in noise-based testing of concurrent software

Software testing, verification & reliability, 2015-05, Vol.25 (3), p.272-309

2015

Volltextzugriff (PDF)

P408 Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experience

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i538-i538

2023

Volltextzugriff (PDF)

P368 Tofacitinib induction efficiency and intracellular cytokine dynamics in ulcerative colitis: Results from clinical practice

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S348-S348

2020

Volltextzugriff (PDF)

P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S352-S353

2020

Volltextzugriff (PDF)

P614 Pregnancy outcomes in women with IBD treated with biosimilar infliximab

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S419-S420

2018

Volltextzugriff (PDF)

P532 Biosimilar infliximab in anti-TNF naive inflammatory bowel disease patients – one-year clinical follow-up

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S350-S351

2017

Volltextzugriff (PDF)

P641 Ustekinumab efficiency as a higher-line therapy in association with serum levels in patients with Crohn’s disease

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S438-S439

2019

Volltextzugriff (PDF)

P487 Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S355-S356

2019

Volltextzugriff (PDF)

P460 Impact of anti-TNFα exposure during pregnancy for maternal inflammatory bowel disease on serologic response to vaccination of exposed children

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S337-S337

2018

Volltextzugriff (PDF)

P734 Anti-TNFa exposure during pregnancy is not associated with increased infection risk in exposed children during the first year of life

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S482-S483

2018

Volltextzugriff (PDF)

Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab

Gastroenterologie a hepatologie, 2018-02, Vol.72 (1), p.20-26

2018

Volltextzugriff (PDF)

Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice

Gastroenterologie a hepatologie, 2019-02, Vol.73 (1), p.25-31

2019

Volltextzugriff (PDF)

Early vedolizumab trough levels are not associated with short-term response in patients with inflammatory bowel disease

Gastroenterologie a hepatologie, 2019-02, Vol.73 (1), p.32-36

2019

Volltextzugriff (PDF)

Biosimilar infliximab in anti-TNF-naïve IBD patients – 1-year clinical follow-up

Gastroenterologie a hepatologie, 2016-12, Vol.70 (6), p.514-522

2016

Volltextzugriff (PDF)

Tofacitinib induction efficacy and safety in ulcerative colitis at week 8 – results from clinical practice

Gastroenterologie a hepatologie, 2020-02, Vol.74 (1), p.28-34

2020

Volltextzugriff (PDF)

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride

Deutsche medizinische Wochenschrift (1946), 2013-04, Vol.138 Suppl 1, p.S16

2013

Volltextzugriff (PDF)

Induction of tolerance to skin graft by previous immunization with an isolated antibody against tissue antigens of a skin graft donor. (Preliminary communication)

Sbornik vedeckych praci Lekarske fakulty Karlovy university v Hradci Kralove, 1969, Vol.12 (5), p.537

1969

Volltextzugriff (PDF)

(1111) - The First Implementation of On-Site MMDx in Heart Transplant Care in Europe: The Initial Experiences

The Journal of heart and lung transplantation, 2024-04, Vol.43 (4), p.S516-S517

2024

Volltextzugriff (PDF)

Mutations in GRK2 cause Jeune syndrome by impairing Hedgehog and canonical Wnt signaling

EMBO molecular medicine, 2020-11, Vol.12 (11), p.e11739-n/a

2020

Volltextzugriff (PDF)

Long-term peritoneal dialysis treatment provokes activation of genes related to adaptive immunity

Physiological research, 2019-01, Vol.68 (5), p.775-783

2019

Volltextzugriff (PDF)

1 – 25 von 113

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(93)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(113)

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial

Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre

A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts

Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre

Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial

Advances in noise-based testing of concurrent software

P408 Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experience

P368 Tofacitinib induction efficiency and intracellular cytokine dynamics in ulcerative colitis: Results from clinical practice

P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project

P614 Pregnancy outcomes in women with IBD treated with biosimilar infliximab

P532 Biosimilar infliximab in anti-TNF naive inflammatory bowel disease patients – one-year clinical follow-up

P641 Ustekinumab efficiency as a higher-line therapy in association with serum levels in patients with Crohn’s disease

P487 Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease

P460 Impact of anti-TNFα exposure during pregnancy for maternal inflammatory bowel disease on serologic response to vaccination of exposed children

P734 Anti-TNFa exposure during pregnancy is not associated with increased infection risk in exposed children during the first year of life

Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab

Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice

Early vedolizumab trough levels are not associated with short-term response in patients with inflammatory bowel disease

Biosimilar infliximab in anti-TNF-naïve IBD patients – 1-year clinical follow-up

Tofacitinib induction efficacy and safety in ulcerative colitis at week 8 – results from clinical practice

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride

Induction of tolerance to skin graft by previous immunization with an isolated antibody against tissue antigens of a skin graft donor. (Preliminary communication)

(1111) - The First Implementation of On-Site MMDx in Heart Transplant Care in Europe: The Initial Experiences

Mutations in GRK2 cause Jeune syndrome by impairing Hedgehog and canonical Wnt signaling

Long-term peritoneal dialysis treatment provokes activation of genes related to adaptive immunity

Suchergebnisse filtern